Just a bit more info!
$SCLX.US$ • The U.S. FDA approved the supplemental New Drug Application for Scilex Holdings' (NASDAQ:SCLX) Gloperba, a liquid, oral of colchicine for the prophylaxis of gout flares in adults.
• The company will launch the drug this month. It will cost $595 for a 150 mL bottle.
• Scilex noted that although colchine is currently available in a 0.6 mg tablet or capsule, many gout patients have chronic kidney disease or gastrointestinal sensitivity making a lower dose preferable. The liquid version will allow providers to prescribe precision dosing.
• The company will launch the drug this month. It will cost $595 for a 150 mL bottle.
• Scilex noted that although colchine is currently available in a 0.6 mg tablet or capsule, many gout patients have chronic kidney disease or gastrointestinal sensitivity making a lower dose preferable. The liquid version will allow providers to prescribe precision dosing.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Jaguar8 : Too expensive but definitely this should be covered by insurance
Trytosaveabit OP Jaguar8 : Right! 600 bucks for 15 teaspoons? I believe I have that correct? Hehehe 10ml per TSP? Well Dr am I right.
Jaguar8 Trytosaveabit OP : Yes expensive. But when competitors come out with compatible formulation, this will drive down price. Or stick to oral colchicine . I forgot there is approx 20 tsps per 100ml
Trytosaveabit OP Jaguar8 : Oh I thought it was 10ml per tsp!
Jaguar8 Trytosaveabit OP : It’s 5ml/tsp and 15ml/tbsp
Trytosaveabit OP Jaguar8 : Hehehe! I was dead smack in the middle! A bit wrong no matter which way it went! Hehehe
Jaguar8 Trytosaveabit OP : Nah we can get mixed up sometimes
Trytosaveabit OP Jaguar8 : Hehehe! You’re to kind![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")